| Pair Name | Cucurbitacin B, Sorafenib | ||
| Phytochemical Name | Cucurbitacin B (PubChem CID: 5281316 ) | ||
| Anticancer drug Name | Sorafenib (PubChem CID: 216239 ) | ||
| Structure of Phytochemical |
|
Download
2D
MOL
3D
MOL
|
|
| Structure of Anticancer Drug |
|
Download
2D
MOL
3D
MOL
|
|
| Pair Name | Cucurbitacin B, Sorafenib | |||
| Disease Info | [ICD-11: 2C12] | Hepatocellular carcinoma | Investigative | |
| Gene Regulation | Up-regulation | Cleavage | CASP3 | hsa836 |
| Up-regulation | Cleavage | CASP9 | hsa842 | |
| Down-regulation | Phosphorylation | STAT3 | hsa6774 | |
| In Vitro Model | Hep-G2 | Hepatoblastoma | Homo sapiens (Human) | CVCL_0027 |
| In Vivo Model | 5×10⁶ HepG2 cells were injected subcutaneously into the right flank of nude mice. | |||
| Result | Sorafenib and CuB exert synergistic antitumor effects through a pathway that may involve STAT3 phosphorylation, and this may represent a promising therapeutic approach for treatment of HCC. | |||
| No. | Title | Href |
|---|---|---|
| 1 | Sorafenib and CuB exert synergistic antitumor effects against hepatocellular carcinoma cells via inhibition of STAT3 phosphorylation. FEBS Open Bio. 2021 Jan;11(1):133-145. doi: 10.1002/2211-5463.13035. | Click |
